Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour. My name is Dae Gon Ha, one of the biotech analysts at Stifel. So with me for the next half hour, we've got Editas Medicine. So from Editas, we have Erick Lucera, Chief Financial Officer and Christine [indiscernible] VP of IR. ...

Core Viewpoint - Editas Medicine reported a narrower loss per share in Q3 2024 compared to the previous year, but its revenues significantly declined due to a lack of upfront payments that were received in the prior year [1][2]. Financial Performance - The company incurred a loss of $0.75 per share in Q3 2024, which is an improvement from the Zacks Consensus Estimate of a loss of $0.76 and a loss of $0.55 per share in the same quarter last year [1]. - Collaboration and other R&D revenues were $0.1 million in Q3 2024, down from $5.3 million in the year-ago quarter, missing the Zacks Consensus Estimate of $7 million [2]. - R&D expenses increased by 18% to $47.6 million compared to $40.5 million in the previous year, driven by higher clinical and manufacturing costs related to the reni-cel program [3]. - General and administrative expenses rose by 21% to $18.1 million due to increased employee-related expenses from a higher headcount [4]. Cash Position - As of September 30, 2024, the company had cash, cash equivalents, and investments totaling $265.1 million, down from $318.3 million as of June 30, 2024 [5]. - The company anticipates that its existing cash and marketable securities, along with an upfront cash payment from DRI and retained payments from Vertex Pharmaceuticals, will fund operations into Q2 2026 [5]. Strategic Developments - Editas has no approved products and is focusing on pipeline development, particularly the reni-cel program for treating sickle cell disease (SCD) [8]. - The company is evaluating the safety and efficacy of reni-cel in the RUBY study and has completed enrollment in both adult and adolescent cohorts [9]. - Editas is seeking a global partner to advance the reni-cel program or potentially out-license rights to alleviate cash constraints [10]. - The company plans to focus resources on in vivo pipeline development, having achieved preclinical proof of concept for therapies targeting SCD and beta thalassemia [12]. Market Performance - Editas shares have declined by 71.6% year-to-date, contrasting with a 3.9% decline in the industry [7].

Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.32%. A quarter ago, it was expected that this genome editing company would post a loss of $0.69 per share when it actually produced a loss of $0.82, delivering a surprise of -18.84%.Over the last four quarters, the compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 ______________ ...

Clinical Development - Achieved in vivo preclinical proof of concept for hematopoietic stem and progenitor cell editing, demonstrating a 29% editing level in HSPCs after a single dose[3] - Induced fetal hemoglobin (HbF) expression in human red blood cells, with an average of 20% HbF expressing cells present one month post-treatment[3] - Reni-cel (renizgamglogene autogedtemcel) is on track to present clinical data at the ASH Annual Meeting on December 7-10, 2024, following the completion of enrollment for adolescent and adult cohorts in the RUBY trial[4] - Completed enrollment of the adult cohort in the EdiTHAL trial for transfusion-dependent beta thalassemia, with additional clinical data expected by year-end 2024[5] Financial Performance - Sold future license fees under the Cas9 license agreement to DRI Healthcare Trust for an upfront cash payment of $57 million, enhancing non-dilutive capital for pipeline development[6] - Ended Q3 2024 with approximately $265 million in cash, cash equivalents, and marketable securities, increasing to approximately $320 million post-receipt of DRI payment[6] Strategic Partnerships - Engaged Moelis & Company LLC to lead the global process for partnering or out-licensing reni-cel, aiming to reduce spending in 2025[6] - Focused on optimal capital use while advancing the in vivo pipeline and evaluating opportunities for reni-cel commercialization[2] Technology and Innovation - The proprietary targeted lipid nanoparticle (tLNP) formulation is key for extrahepatic tissue delivery, positioning the company for leadership in in vivo programmable gene editing[2] - The company aims to deliver transformative genomic medicines for serious diseases, leveraging CRISPR/Cas12a and Cas9 genome editing systems[8]

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on ...

Editas Medicine (EDIT) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, t ...

Shares of Editas Medicine (EDIT) plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its lead gene editing therapy, reni-cel, which is being developed for certain non-malignant hematologic diseases, or potentially out-license rights to the treatment entirely, amid a significant cash crunch. Editas firmly believes that this decision is in the best interests of its patients and shareholders, as a potential partnership agreement would allow for further development and ultim ...

Editas Medicine, Inc. (EDIT) announced that it has entered into a collaboration and nonexclusive license agreement with Canada-based privately held company Genevant Sciences to develop in vivo gene editing medicines. Shares of Editas were up 2.4% in after-hours trading on Oct. 21, following the announcement of the news. The partnership aims to leverage Editas' CRISPR Cas12a genome editing systems with Genevant's proprietary lipid nanoparticle (LNP) technology to develop novel mRNA-LNP gene editing therapies ...

Company Overview - Editas Medicine, Inc. held a Strategic Update Conference Call on October 22, 2024, at 8:00 AM ET, featuring key executives including the CEO, CFO, and Chief Scientific Officer [1]. Participants - The conference call included participation from various financial institutions such as Citi, Barclays, Baird, Wells Fargo, and JPMorgan Chase, among others [1]. Future Expectations - The company made forward-looking statements regarding its future expectations, plans, and prospects, which are protected under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 [2].